Publications

Categories
Zanidatamab
June 2, 2023
Lancet Oncology
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Harding et al.
Zanidatamab
June 2, 2023
ASCO
Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2-amplified Biliary Tract Cancer (BTC)
Pant et al.
ZW171
May 19, 2023
PEGS
Engineering and Preclinical Development of ZW171: A 2+1 Format Anti-MSLN T Cell Engager
Piscitelli et al.
Preclinical
May 15, 2023 - May 19, 2023
PEGS
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Bhojane et al.
Preclinical
May 15, 2023 - May 19, 2023
PEGS
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
May 10, 2023
STING & TLR-Targeting Therapies Summit
Evaluation of TLR7-agonists as payloads for immune-stimulating antibody conjugates
Graham Garnett
Preclinical
April 18, 2023
AACR
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Newhook et al.
Zanidatamab
April 18, 2023
AACR
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a Phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
Shpektor et al.
Preclinical
April 17, 2023
AACR
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Hernández et al.
Preclinical
April 17, 2023
AACR
Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Colombo et al.
ZW191
April 17, 2023
AACR
ZW191, a novel FRα-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Lawn et al.
Preclinical
April 17, 2023
AACR
ZW270, A Conditionally Masked IL-12 Cytokine Fusion Protein Displaying Potent Anti-tumour Activity Absent of Systemic Toxicity
Escalante et al.